Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00221052
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : October 11, 2006
Information provided by:

September 13, 2005
September 22, 2005
October 11, 2006
June 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00221052 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men
Relation Between Reduction of the Inflammatory Status and Glucose Metabolism in Healthy Overweight Men

Overweight increases the risk to develop chronic diseases including type-2 diabetes and cardiovascular disease. The low-grade inflammatory status often seen in overweight subjects is thought to play an important role in disease development.

The purpose of this study is to determine the role of inflammation on glucose metabolism and insulin resistance. In this study the effect of the anti-inflammatory treatment diclofenac on markers of inflammation and on parameters of glucose metabolism will be studied.

Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
  • Overweight
  • Obesity
  • Inflammation
Drug: Diclofenac
Not Provided
van Erk MJ, Wopereis S, Rubingh C, van Vliet T, Verheij E, Cnubben NH, Pedersen TL, Newman JW, Smilde AK, van der Greef J, Hendriks HF, van Ommen B. Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study. BMC Med Genomics. 2010 Feb 23;3:5. doi: 10.1186/1755-8794-3-5.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
July 2005
Not Provided

Inclusion Criteria:

  • Body Mass Index (BMI): 25.1 – 32.0 kg/m2
  • Normal Dutch eating habits

Exclusion Criteria:

  • diabetes, cardiovascular disease or hypertension
  • Not suitable to receive diclofenac treatment
  • Smoking
  • Extreme physical activity (more than 6 hours/week)
  • Reported slimming or medically prescribed diet
Sexes Eligible for Study: Male
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Principal Investigator: Trinette van Vliet, PhD TNO Quality of Life, Location Zeist
October 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP